{"id": "264329", "url": "https://fevir.net/resources/Citation/264329", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"], "versionId": "15", "lastUpdated": "2025-10-13T12:34:35.118Z"}, "title": "37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.", "author": [{"name": "Computable Publishing\u00ae: MEDLINE-to-FEvIR Converter"}], "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "contained": [{"id": "contributor0", "name": [{"given": ["Qingyang"], "family": "Shi"}], "identifier": [{"type": {"text": "ORCID", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "PRN", "display": "Provider number"}]}, "value": "0000-0003-4299-5889", "system": "https://orcid.org/"}], "resourceType": "Practitioner"}, {"id": "contributor1", "name": [{"given": ["Kailei"], "family": "Nong"}], "resourceType": "Practitioner"}, {"id": "contributor2", "name": [{"given": ["Per Olav"], "family": "Vandvik"}], "resourceType": "Practitioner"}, {"id": "contributor3", "name": [{"given": ["Gordon H"], "family": "Guyatt"}], "resourceType": "Practitioner"}, {"id": "contributor4", "name": [{"given": ["Oliver"], "family": "Schnell"}], "resourceType": "Practitioner"}, {"id": "contributor5", "name": [{"given": ["Lars"], "family": "Ryd\u00e9n"}], "resourceType": "Practitioner"}, {"id": "contributor6", "name": [{"given": ["Nikolaus"], "family": "Marx"}], "resourceType": "Practitioner"}, {"id": "contributor7", "name": [{"given": ["Frank C"], "family": "Brosius"}], "resourceType": "Practitioner"}, {"id": "contributor8", "name": [{"given": ["Reem A"], "family": "Mustafa"}], "resourceType": "Practitioner"}, {"id": "contributor9", "name": [{"given": ["Arnav"], "family": "Agarwal"}], "resourceType": "Practitioner"}, {"id": "contributor10", "name": [{"given": ["Xinyu"], "family": "Zou"}], "resourceType": "Practitioner"}, {"id": "contributor11", "name": [{"given": ["Yunhe"], "family": "Mao"}], "resourceType": "Practitioner"}, {"id": "contributor12", "name": [{"given": ["Aminreza"], "family": "Asadollahifar"}], "resourceType": "Practitioner"}, {"id": "contributor13", "name": [{"given": ["Saifur Rahman"], "family": "Chowdhury"}], "resourceType": "Practitioner"}, {"id": "contributor14", "name": [{"given": ["Chunjuan"], "family": "Zhai"}], "resourceType": "Practitioner"}, {"id": "contributor15", "name": [{"given": ["Sana"], "family": "Gupta"}], "resourceType": "Practitioner"}, {"id": "contributor16", "name": [{"given": ["Ya"], "family": "Gao"}], "resourceType": "Practitioner"}, {"id": "contributor17", "name": [{"given": ["Jo\u00e3o Pedro"], "family": "Lima"}], "resourceType": "Practitioner"}, {"id": "contributor18", "name": [{"given": ["Kenji"], "family": "Numata"}], "resourceType": "Practitioner"}, {"id": "contributor19", "name": [{"given": ["Zhi"], "family": "Qiao"}], "resourceType": "Practitioner"}, {"id": "contributor20", "name": [{"given": ["Qinlin"], "family": "Fan"}], "resourceType": "Practitioner"}, {"id": "contributor21", "name": [{"given": ["Qinbo"], "family": "Yang"}], "resourceType": "Practitioner"}, {"id": "contributor22", "name": [{"given": ["Yinghui"], "family": "Jin"}], "resourceType": "Practitioner"}, {"id": "contributor23", "name": [{"given": ["Long"], "family": "Ge"}], "resourceType": "Practitioner"}, {"id": "contributor24", "name": [{"given": ["Qiuyu"], "family": "Yang"}], "resourceType": "Practitioner"}, {"id": "contributor25", "name": [{"given": ["Hongfei"], "family": "Zhu"}], "resourceType": "Practitioner"}, {"id": "contributor26", "name": [{"given": ["Fan"], "family": "Yang"}], "resourceType": "Practitioner"}, {"id": "contributor27", "name": [{"given": ["Zhe"], "family": "Chen"}], "resourceType": "Practitioner"}, {"id": "contributor28", "name": [{"given": ["Xi"], "family": "Lu"}], "resourceType": "Practitioner"}, {"id": "contributor29", "name": [{"given": ["Siyu"], "family": "He"}], "resourceType": "Practitioner"}, {"id": "contributor30", "name": [{"given": ["Xiangyang"], "family": "Chen"}], "resourceType": "Practitioner"}, {"id": "contributor31", "name": [{"given": ["Xiafei"], "family": "Lyu"}], "resourceType": "Practitioner"}, {"id": "contributor32", "name": [{"given": ["Xingxing"], "family": "An"}], "resourceType": "Practitioner"}, {"id": "contributor33", "name": [{"given": ["Yaolong"], "family": "Chen"}], "resourceType": "Practitioner"}, {"id": "contributor34", "name": [{"given": ["Qiukui"], "family": "Hao"}], "resourceType": "Practitioner"}, {"id": "contributor35", "name": [{"given": ["Eberhard"], "family": "Standl"}], "resourceType": "Practitioner"}, {"id": "contributor36", "name": [{"given": ["Reed"], "family": "Siemieniuk"}], "resourceType": "Practitioner"}, {"id": "contributor37", "name": [{"given": ["Thomas"], "family": "Agoritsas"}], "resourceType": "Practitioner"}, {"id": "contributor38", "name": [{"given": ["Haoming"], "family": "Tian"}], "resourceType": "Practitioner"}, {"id": "contributor39", "name": [{"given": ["Sheyu"], "family": "Li"}], "identifier": [{"type": {"text": "ORCID", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "PRN", "display": "Provider number"}]}, "value": "0000-0003-0060-0287", "system": "https://orcid.org/"}], "resourceType": "Practitioner"}, {"id": "meshHeading0", "content": [{"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}], "classifier": [{"coding": [{"code": "D000328", "system": "https://www.nlm.nih.gov/mesh", "display": "Adult", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}], "classifier": [{"coding": [{"code": "D006801", "system": "https://www.nlm.nih.gov/mesh", "display": "Humans", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is Major topic"}]}, {"type": {"text": "qualifier"}, "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49487", "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "display": "No"}]}]}], "classifier": [{"coding": [{"code": "Q000188", "system": "https://www.nlm.nih.gov/mesh", "display": "drug therapy"}]}]}], "classifier": [{"coding": [{"code": "D003924", "system": "https://www.nlm.nih.gov/mesh", "display": "Diabetes Mellitus, Type 2", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is Major topic"}]}, {"type": {"text": "qualifier"}, "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49487", "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "display": "No"}]}]}], "classifier": [{"coding": [{"code": "Q000009", "system": "https://www.nlm.nih.gov/mesh", "display": "adverse effects"}]}]}], "classifier": [{"coding": [{"code": "D000077203", "system": "https://www.nlm.nih.gov/mesh", "display": "Sodium-Glucose Transporter 2 Inhibitors", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49487", "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "display": "No"}]}]}], "classifier": [{"coding": [{"code": "Q000009", "system": "https://www.nlm.nih.gov/mesh", "display": "adverse effects"}]}]}], "classifier": [{"coding": [{"code": "D000451", "system": "https://www.nlm.nih.gov/mesh", "display": "Mineralocorticoid Receptor Antagonists", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}], "classifier": [{"coding": [{"code": "D000071076", "system": "https://www.nlm.nih.gov/mesh", "display": "Network Meta-Analysis", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49487", "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "display": "No"}]}]}], "classifier": [{"coding": [{"code": "Q000627", "system": "https://www.nlm.nih.gov/mesh", "display": "therapeutic use"}]}]}], "classifier": [{"coding": [{"code": "D000067757", "system": "https://www.nlm.nih.gov/mesh", "display": "Glucagon-Like Peptide-1 Receptor", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}], "classifier": [{"coding": [{"code": "D011788", "system": "https://www.nlm.nih.gov/mesh", "display": "Quality of Life", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is Major topic"}]}], "classifier": [{"coding": [{"code": "D007676", "system": "https://www.nlm.nih.gov/mesh", "display": "Kidney Failure, Chronic", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is Major topic"}]}, {"type": {"text": "qualifier"}, "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49487", "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "display": "No"}]}]}], "classifier": [{"coding": [{"code": "Q000188", "system": "https://www.nlm.nih.gov/mesh", "display": "drug therapy"}]}]}], "classifier": [{"coding": [{"code": "D006333", "system": "https://www.nlm.nih.gov/mesh", "display": "Heart Failure", "userSelected": false}]}], "freeToShare": true}, {"type": {"text": "components (if present) include qualifier codings", "coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}], "classifier": [{"coding": [{"code": "D016032", "system": "https://www.nlm.nih.gov/mesh", "display": "Randomized Controlled Trials as Topic", "userSelected": false}]}], "freeToShare": true}], "resourceType": "ArtifactAssessment", "artifactReference": {"type": "Citation", "reference": "#"}}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "264329", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"value": "37024129", "system": "https://pubmed.ncbi.nlm.nih.gov"}], "statusDate": [{"period": {"end": "2023-04-10T06:42:00.000Z"}, "activity": {"coding": [{"code": "pubmed-pubstatus-medline", "system": "http://hl7.org/fhir/citation-status-type", "display": "PubMed Pubstatus of Medline"}]}}, {"period": {"end": "2023-04-06T20:43:00.000Z"}, "activity": {"coding": [{"code": "pubmed-pubstatus-entrez", "system": "http://hl7.org/fhir/citation-status-type", "display": "PubMed Pubstatus of Entrez"}]}}, {"period": {"end": "2023-04-07T06:00:00.000Z"}, "activity": {"coding": [{"code": "pubmed-pubstatus-pubmed", "system": "http://hl7.org/fhir/citation-status-type", "display": "PubMed Pubstatus of Pubmed"}]}}, {"period": {"end": "2023-04-06"}, "activity": {"coding": [{"code": "pubmed-pubstatus-pmc-release", "system": "http://hl7.org/fhir/citation-status-type", "display": "PubMed Pubstatus of PMC release"}]}}], "useContext": [{"code": {"code": "fevir-platform-use", "system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "display": "FEvIR Platform Use"}, "valueCodeableConcept": {"coding": [{"code": "medline-base", "system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "display": "Medline Base", "userSelected": false}]}}], "approvalDate": "2023-04-10", "currentState": [{"coding": [{"code": "medline-medline", "system": "http://hl7.org/fhir/citation-status-type", "display": "Medline Citation Status of Medline"}]}, {"coding": [{"code": "pubmed-publication-status-epublish", "system": "http://hl7.org/fhir/citation-status-type", "display": "PubMed PublicationStatus of epublish"}]}], "resourceType": "Citation", "citedArtifact": {"title": [{"text": "Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.", "type": [{"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/title-type", "display": "Primary title"}]}], "language": {"coding": [{"system": "urn:ietf:bcp:47", "code": "en", "display": "English"}]}}], "abstract": [{"text": "**OBJECTIVE:** To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options.\n<AbstractText Label=\"DESIGN\">Systematic review and network meta-analysis.\n<AbstractText Label=\"DATA SOURCES\">Ovid Medline, Embase, and Cochrane Central up to 14 October 2022.\n<AbstractText Label=\"ELIGIBILITY CRITERIA FOR SELECTING STUDIES\">Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach.\n**RESULTS:** The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular death. Only GLP-1 receptor agonists reduce non-fatal stroke; SGLT-2 inhibitors are superior to other drugs in reducing end stage kidney disease. GLP-1 receptor agonists and probably SGLT-2 inhibitors and tirzepatide improve quality of life. Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably results in the largest reduction in body weight (mean difference -8.57 kg; moderate certainty). Basal insulin (mean difference 2.15 kg; moderate certainty) and thiazolidinediones (mean difference 2.81 kg; moderate certainty) probably result in the largest increases in body weight. Absolute benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone vary in people with type 2 diabetes, depending on baseline risks for cardiovascular and kidney outcomes (https://matchit.magicevidence.org/230125dist-diabetes).\n**CONCLUSIONS:** This network meta-analysis extends knowledge beyond confirming the substantial benefits with the use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing adverse cardiovascular and kidney outcomes and death by adding information on finerenone and tirzepatide. These findings highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes.\n<AbstractText Label=\"SYSTEMATIC REVIEW REGISTRATION\">PROSPERO CRD42022325948.", "type": {"coding": [{"code": "primary-human-use", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type", "display": "Primary human use"}]}, "copyright": "\u00a9 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ."}], "relatesTo": [{"type": "cites", "citation": "Gregg EW, Jakicic JM, Blackburn G, et al. Look AHEAD Research Group . Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913-21. 10.1016/S2213-8587(16)30162-0.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/27595918/", "identifier": {"value": "27595918", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Palmer SC, Tendal B, Mustafa RA, et al. . Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573. 10.1136/bmj.m4573.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/33441402/", "identifier": {"value": "33441402", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Li S, Vandvik PO, Lytvyn L, et al. . SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ 2021;373:n1091. 10.1136/bmj.n1091.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/33975892/", "identifier": {"value": "33975892", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Bakris GL, Agarwal R, Anker SD, et al. FIDELIO-DKD Investigators . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-29. 10.1056/NEJMoa2025845.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/33264825/", "identifier": {"value": "33264825", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Pitt B, Filippatos G, Agarwal R, et al. FIGARO-DKD Investigators . Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-63. 10.1056/NEJMoa2110956.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/34449181/", "identifier": {"value": "34449181", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Rosenstock J, Wysham C, Fr\u00edas JP, et al. . Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:143-55. 10.1016/S0140-6736(21)01324-6.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/34186022/", "identifier": {"value": "34186022", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Fr\u00edas JP, Davies MJ, Rosenstock J, et al. SURPASS-2 Investigators . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-15. 10.1056/NEJMoa2107519.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/34170647/", "identifier": {"value": "34170647", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Ludvik B, Giorgino F, J\u00f3dar E, et al. . Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021;398:583-98. 10.1016/S0140-6736(21)01443-4.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/34370970/", "identifier": {"value": "34370970", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Del Prato S, Kahn SE, Pavo I, et al. SURPASS-4 Investigators . Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811-24. 10.1016/S0140-6736(21)02188-7.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/34672967/", "identifier": {"value": "34672967", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Dahl D, Onishi Y, Norwood P, et al. . Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA 2022;327:534-45. 10.1001/jama.2022.0078.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/35133415/", "identifier": {"value": "35133415", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Ryd\u00e9n L, Standl E. After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk. N Engl J Med 2022;387:1136-8. 10.1056/NEJMe2210531.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/36130002/", "identifier": {"value": "36130002", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Nathan DM, Lachin JM, Balasubramanyam A, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 2022;387:1063-74. 10.1056/NEJMoa2200433.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/36129996/", "identifier": {"value": "36129996", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Nathan DM, Lachin JM, Bebu I, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022;387:1075-88. 10.1056/NEJMoa2200436.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/36129997/", "identifier": {"value": "36129997", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Marx N, Ryden L, Brosius F, et al. . Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Res Clin Pract 2021;177:108870. 10.1016/j.diabres.2021.108870.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/34044026/", "identifier": {"value": "34044026", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. 10.1136/bmj.n71.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/33782057/", "identifier": {"value": "33782057", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Hutton B, Salanti G, Caldwell DM, et al. . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84. 10.7326/M14-2385.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/26030634/", "identifier": {"value": "26030634", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Guyatt G, Busse J. Methods Commentary: Risk of Bias in Randomized Trials 1. DistillerSR. 2011. https://www.distillersr.com/resources/methodological-resources/risk-of-bias-commentary."}, {"type": "cites", "citation": "Levin A, Agarwal R, Herrington WG, et al. participant authors of the International Society of Nephrology\u2019s 1st International Consensus Meeting on Defining Kidney Failure in Clinical Trials . International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int 2020;98:849-59. 10.1016/j.kint.2020.07.013.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/32998816/", "identifier": {"value": "32998816", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "R\u00fccker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods 2012;3:312-24. 10.1002/jrsm.1058.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/26053424/", "identifier": {"value": "26053424", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Shi Q, Wang Y, Hao Q, et al. . Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2022;399:259-69. 10.1016/S0140-6736(21)01640-8.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/34895470/", "identifier": {"value": "34895470", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Bhaumik DK, Amatya A, Normand S-L, et al. . Meta-Analysis of Rare Binary Adverse Event Data. J Am Stat Assoc 2012;107:555-67. 10.1080/01621459.2012.664484.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/23734068/", "identifier": {"value": "23734068", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110. 10.1002/jrsm.1044.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/26062084/", "identifier": {"value": "26062084", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "K\u00f6nig J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. Stat Med 2013;32:5414-29. 10.1002/sim.6001.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/24123165/", "identifier": {"value": "24123165", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Wiksten A, Hawkins N, Piepho H-P, Gsteiger S. Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis. Value Health 2020;23:918-27. 10.1016/j.jval.2020.03.010.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/32762994/", "identifier": {"value": "32762994", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Efthimiou O, R\u00fccker G, Schwarzer G, Higgins JPT, Egger M, Salanti G. Network meta-analysis of rare events using the Mantel-Haenszel method. Stat Med 2019;38:2992-3012. 10.1002/sim.8158.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/30997687/", "identifier": {"value": "30997687", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Schandelmaier S, Briel M, Varadhan R, et al. . Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 2020;192:E901-6. 10.1503/cmaj.200077.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/32778601/", "identifier": {"value": "32778601", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Balshem H, Helfand M, Sch\u00fcnemann HJ, et al. . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. 10.1016/j.jclinepi.2010.07.015.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/21208779/", "identifier": {"value": "21208779", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Davies AL, Papakonstantinou T, Nikolakopoulou A, R\u00fccker G, Galla T. Network meta-analysis and random walks. Stat Med 2022;41:2091-114. 10.1002/sim.9346.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/35293631/", "identifier": {"value": "35293631", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Puhan MA, Sch\u00fcnemann HJ, Murad MH, et al. GRADE Working Group . A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. 10.1136/bmj.g5630.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/25252733/", "identifier": {"value": "25252733", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol 2021;137:163-75. 10.1016/j.jclinepi.2021.03.026.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/33857619/", "identifier": {"value": "33857619", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol 2022;150:216-24. 10.1016/j.jclinepi.2022.07.014", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/35934265/", "identifier": {"value": "35934265", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE working group . GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 2020;371:m3900. 10.1136/bmj.m3900.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/33177059/", "identifier": {"value": "33177059", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Phillips MR, Sadeghirad B, Busse JW, et al. . Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study. BMJ Open 2022;12:e056400. 10.1136/bmjopen-2021-056400.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/35688599/", "identifier": {"value": "35688599", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Buchan TA, Malik A, Chan C, et al. . Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses. Heart 2021;107:1962-73. 10.1136/heartjnl-2021-319243.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/33833070/", "identifier": {"value": "33833070", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Wright AK, Carr MJ, Kontopantelis E, et al. . Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care 2022;45:909-18. 10.2337/dc21-1113.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/35100355/", "identifier": {"value": "35100355", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Rossing P, Anker SD, Filippatos G, et al. FIDELIO-DKD and FIGARO-DKD Investigators . Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care 2022;45:2991-8. 10.2337/dc22-0294.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/35972218/", "identifier": {"value": "35972218", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Sato N, Ajioka M, Yamada T, et al. ARTS-HF Japan study group . A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J 2016;80:1113-22. 10.1253/circj.CJ-16-0122.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/27074824/", "identifier": {"value": "27074824", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Ruilope LM, Pitt B, Anker SD, et al. . Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant 2023;38:372-83.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/35451488/", "identifier": {"value": "35451488", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Bayer. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction \u2265 40% (LVEF \u2265 40%). Clinicaltrials.gov. 2022. https://clinicaltrials.gov/ct2/show/NCT04435626."}, {"type": "cites", "citation": "Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management. Pharmacol Res 2021;172:105835. 10.1016/j.phrs.2021.105835.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/34438065/", "identifier": {"value": "34438065", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Eli Lilly and Company. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT). clinicaltrials.gov 2022. https://clinicaltrials.gov/ct2/show/NCT04255433."}, {"type": "cites", "citation": "Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:642-53. 10.1038/s41574-020-0399-8.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/32929230/", "identifier": {"value": "32929230", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Liu J, Li L, Li S, et al. . Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020;22:1619-27. 10.1111/dom.14075.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/32364674/", "identifier": {"value": "32364674", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Lin C, Zhu X, Cai X, et al. . SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol 2021;20:91. 10.1186/s12933-021-01276-9.", "classifier": [{"coding": [{"code": "D016428", "system": "http://hl7.org/fhir/citation-artifact-classifier", "display": "Journal Article"}]}], "targetReference": {"type": "Citation", "reference": "https://pubmed.ncbi.nlm.nih.gov/33910574/", "identifier": {"value": "33910574", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}, {"type": "comment-in", "citation": "Acad Emerg Med. 2024 Aug;31(8):832-834. doi: 10.1111/acem.14922.", "classifier": [{"coding": [{"code": "D016420", "system": "https://www.nlm.nih.gov/mesh", "display": "Comment", "userSelected": false}]}], "targetReference": {"reference": "https://pubmed.ncbi.nlm.nih.gov/38661224/", "identifier": {"value": "38661224", "system": "https://pubmed.ncbi.nlm.nih.gov", "assigner": {"display": "NLM"}}}}], "identifier": [{"value": "37024129", "system": "https://pubmed.ncbi.nlm.nih.gov"}, {"value": "PMC10077111", "system": "https://www.ncbi.nlm.nih.gov/pmc/"}, {"value": "10.1136/bmj-2022-074068", "system": "https://doi.org"}], "webLocation": [{"url": "https://pubmed.ncbi.nlm.nih.gov/37024129/", "classifier": [{"coding": [{"code": "abstract", "system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier", "display": "Abstract"}]}]}, {"url": "https://doi.org/10.1136/bmj-2022-074068", "classifier": [{"coding": [{"code": "doi-based", "system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier", "display": "DOI Based"}]}]}], "classification": [{"type": {"coding": [{"code": "publishing-model", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Publishing Model", "userSelected": false}]}, "classifier": [{"coding": [{"code": "Electronic", "system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "display": "Electronic", "userSelected": false}]}]}, {"type": {"coding": [{"code": "chemical", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Chemical", "userSelected": false}]}, "classifier": [{"coding": [{"code": "D000077203", "system": "https://www.nlm.nih.gov/mesh", "display": "Sodium-Glucose Transporter 2 Inhibitors", "userSelected": false}]}, {"coding": [{"code": "D000451", "system": "https://www.nlm.nih.gov/mesh", "display": "Mineralocorticoid Receptor Antagonists", "userSelected": false}]}, {"coding": [{"code": "D000067757", "system": "https://www.nlm.nih.gov/mesh", "display": "Glucagon-Like Peptide-1 Receptor", "userSelected": false}]}]}, {"type": {"coding": [{"code": "mesh-heading", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "MeSH heading"}]}, "artifactAssessment": [{"type": "ArtifactAssessment", "reference": "#meshHeading0"}]}, {"type": {"coding": [{"code": "publication-type", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Publication type"}]}, "classifier": [{"coding": [{"code": "D017418", "system": "https://www.nlm.nih.gov/mesh", "display": "Meta-Analysis", "userSelected": false}]}, {"coding": [{"code": "D000078182", "system": "https://www.nlm.nih.gov/mesh", "display": "Systematic Review", "userSelected": false}]}, {"coding": [{"code": "D016428", "system": "https://www.nlm.nih.gov/mesh", "display": "Journal Article", "userSelected": false}]}]}, {"type": {"coding": [{"code": "knowledge-artifact-type", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Knowledge Artifact Type", "userSelected": false}]}, "classifier": [{"coding": [{"code": "D016428", "system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier", "display": "Journal Article", "userSelected": false}]}], "artifactAssessment": [{"display": "Classifier added by Computable Publishing LLC"}]}, {"type": {"coding": [{"code": "citation-subset", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type", "display": "Citation subset", "userSelected": false}]}, "classifier": [{"coding": [{"code": "IM", "system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset", "display": "IM", "userSelected": false}]}]}], "contributorship": {"entry": [{"affiliation": [{"display": "Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Shi Q", "reference": "#contributor0"}, "forenameInitials": "Q"}, {"affiliation": [{"display": "Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Nong K", "reference": "#contributor1"}, "forenameInitials": "K"}, {"affiliation": [{"display": "Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway."}], "contributor": {"type": "Practitioner", "display": "Vandvik PO", "reference": "#contributor2"}, "forenameInitials": "PO"}, {"affiliation": [{"display": "Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."}], "contributor": {"type": "Practitioner", "display": "Guyatt GH", "reference": "#contributor3"}, "forenameInitials": "GH"}, {"affiliation": [{"display": "Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany."}], "contributor": {"type": "Practitioner", "display": "Schnell O", "reference": "#contributor4"}, "forenameInitials": "O"}, {"affiliation": [{"display": "Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden."}], "contributor": {"type": "Practitioner", "display": "Ryd\u00e9n L", "reference": "#contributor5"}, "forenameInitials": "L"}, {"affiliation": [{"display": "Clinic for Cardiology, Angiology, and Intensive Care Medicine, RWTH Aachen University, University Hospital Aachen, Aachen, Germany."}], "contributor": {"type": "Practitioner", "display": "Marx N", "reference": "#contributor6"}, "forenameInitials": "N"}, {"affiliation": [{"display": "Division of Nephrology, University of Arizona College of Medicine Tucson, Tucson, AZ, USA."}], "contributor": {"type": "Practitioner", "display": "Brosius FC", "reference": "#contributor7"}, "forenameInitials": "FC"}, {"affiliation": [{"display": "Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas, Kansas City, MI, USA."}], "contributor": {"type": "Practitioner", "display": "Mustafa RA", "reference": "#contributor8"}, "forenameInitials": "RA"}, {"affiliation": [{"display": "Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."}, {"display": "Department of Medicine, McMaster University, Hamilton, ON, Canada."}], "contributor": {"type": "Practitioner", "display": "Agarwal A", "reference": "#contributor9"}, "forenameInitials": "A"}, {"affiliation": [{"display": "Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Zou X", "reference": "#contributor10"}, "forenameInitials": "X"}, {"affiliation": [{"display": "Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Mao Y", "reference": "#contributor11"}, "forenameInitials": "Y"}, {"affiliation": [{"display": "Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran."}], "contributor": {"type": "Practitioner", "display": "Asadollahifar A", "reference": "#contributor12"}, "forenameInitials": "A"}, {"affiliation": [{"display": "Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."}], "contributor": {"type": "Practitioner", "display": "Chowdhury SR", "reference": "#contributor13"}, "forenameInitials": "SR"}, {"affiliation": [{"display": "Department of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China."}], "contributor": {"type": "Practitioner", "display": "Zhai C", "reference": "#contributor14"}, "forenameInitials": "C"}, {"affiliation": [{"display": "Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."}], "contributor": {"type": "Practitioner", "display": "Gupta S", "reference": "#contributor15"}, "forenameInitials": "S"}, {"affiliation": [{"display": "Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."}, {"display": "Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China."}], "contributor": {"type": "Practitioner", "display": "Gao Y", "reference": "#contributor16"}, "forenameInitials": "Y"}, {"affiliation": [{"display": "Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."}], "contributor": {"type": "Practitioner", "display": "Lima JP", "reference": "#contributor17"}, "forenameInitials": "JP"}, {"affiliation": [{"display": "Department of Emergency Medicine, St Marianna University School of Medicine, Kawasaki, Japan."}], "contributor": {"type": "Practitioner", "display": "Numata K", "reference": "#contributor18"}, "forenameInitials": "K"}, {"affiliation": [{"display": "West China School of Medicine, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Qiao Z", "reference": "#contributor19"}, "forenameInitials": "Z"}, {"affiliation": [{"display": "Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Fan Q", "reference": "#contributor20"}, "forenameInitials": "Q"}, {"affiliation": [{"display": "Department of Nephrology, National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Yang Q", "reference": "#contributor21"}, "forenameInitials": "Q"}, {"affiliation": [{"display": "Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China."}], "contributor": {"type": "Practitioner", "display": "Jin Y", "reference": "#contributor22"}, "forenameInitials": "Y"}, {"affiliation": [{"display": "Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China."}], "contributor": {"type": "Practitioner", "display": "Ge L", "reference": "#contributor23"}, "forenameInitials": "L"}, {"affiliation": [{"display": "Evidence-Based Nursing Centre, School of Nursing, Lanzhou University, Lanzhou, China."}], "contributor": {"type": "Practitioner", "display": "Yang Q", "reference": "#contributor24"}, "forenameInitials": "Q"}, {"affiliation": [{"display": "Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China."}], "contributor": {"type": "Practitioner", "display": "Zhu H", "reference": "#contributor25"}, "forenameInitials": "H"}, {"affiliation": [{"display": "Department of Endocrinology and Metabolism, Chengdu Fifth People's Hospital, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Yang F", "reference": "#contributor26"}, "forenameInitials": "F"}, {"affiliation": [{"display": "Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine, Tianjin, China."}], "contributor": {"type": "Practitioner", "display": "Chen Z", "reference": "#contributor27"}, "forenameInitials": "Z"}, {"affiliation": [{"display": "Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Lu X", "reference": "#contributor28"}, "forenameInitials": "X"}, {"affiliation": [{"display": "Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "He S", "reference": "#contributor29"}, "forenameInitials": "S"}, {"affiliation": [{"display": "Department of Endocrinology and Metabolism, First People's Hospital of Shuangliu District, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Chen X", "reference": "#contributor30"}, "forenameInitials": "X"}, {"affiliation": [{"display": "Department of Radiology, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Lyu X", "reference": "#contributor31"}, "forenameInitials": "X"}, {"affiliation": [{"display": "Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "An X", "reference": "#contributor32"}, "forenameInitials": "X"}, {"affiliation": [{"display": "Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China."}], "contributor": {"type": "Practitioner", "display": "Chen Y", "reference": "#contributor33"}, "forenameInitials": "Y"}, {"affiliation": [{"display": "School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada."}], "contributor": {"type": "Practitioner", "display": "Hao Q", "reference": "#contributor34"}, "forenameInitials": "Q"}, {"affiliation": [{"display": "Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany."}], "contributor": {"type": "Practitioner", "display": "Standl E", "reference": "#contributor35"}, "forenameInitials": "E"}, {"affiliation": [{"display": "Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."}], "contributor": {"type": "Practitioner", "display": "Siemieniuk R", "reference": "#contributor36"}, "forenameInitials": "R"}, {"affiliation": [{"display": "Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada."}, {"display": "Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland."}], "contributor": {"type": "Practitioner", "display": "Agoritsas T", "reference": "#contributor37"}, "forenameInitials": "T"}, {"affiliation": [{"display": "Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China."}], "contributor": {"type": "Practitioner", "display": "Tian H", "reference": "#contributor38"}, "forenameInitials": "H"}, {"affiliation": [{"display": "Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China lisheyu@gmail.com."}], "contributor": {"type": "Practitioner", "display": "Li S", "reference": "#contributor39"}, "forenameInitials": "S"}], "complete": true}, "publicationForm": [{"volume": "381", "pageString": "e074068", "articleDate": "2023-04-06", "citedMedium": {"coding": [{"code": "internet", "system": "http://terminology.hl7.org/CodeSystem/cited-medium", "display": "Internet"}]}, "publishedIn": {"type": {"coding": [{"code": "D020492", "system": "http://terminology.hl7.org/CodeSystem/published-in-type", "display": "Periodical"}]}, "title": "BMJ (Clinical research ed.)", "identifier": [{"type": {"text": "Electronic ISSN Type", "coding": [{"code": "Electronic", "system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn", "display": "Electronic"}]}, "value": "1756-1833", "system": "https://portal.issn.org"}, {"type": {"text": "ISOAbbreviation", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "value": "BMJ", "system": "https://www.issn.org/services/online-services/access-to-the-ltwa/"}, {"type": {"text": "ISSN Linking", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "value": "0959-8138", "system": "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/"}, {"type": {"text": "Medline Title Abbreviation", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "value": "BMJ", "system": "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html"}, {"type": {"text": "NLM Unique ID", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "value": "8900488", "system": "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local"}], "publisherLocation": "England"}}, {"articleDate": "2023-04-06", "citedMedium": {"coding": [{"code": "internet-without-issue", "system": "http://terminology.hl7.org/CodeSystem/cited-medium", "display": "Internet without issue"}]}}]}, "classification": [{"type": {"coding": [{"code": "citation-source", "system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "display": "Citation Source"}]}, "classifier": [{"text": "MEDLINE"}]}, {"type": {"coding": [{"code": "medline-owner", "system": "http://terminology.hl7.org/CodeSystem/citation-classification-type", "display": "MEDLINE Citation Owner"}]}, "classifier": [{"coding": [{"code": "NLM", "system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value", "display": "National Library of Medicine, Index Section", "userSelected": false}]}]}], "lastReviewDate": "2025-03-14", "description": "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."}